Tetraphase Pharmaceuticals was established to advance and commercialize breakthrough synthetic chemistry developed by world-leading organic chemist Professor Andrew G. Myers at Harvard University. The Company’s initial focus is on the discovery and development of novel antibiotics to treat drug-resistant infections. This enabling technology also provides meaningful opportunities in inflammation and cancer.

Flagship General Partner Doug Cole is on the Board of Directors.

www.tphase.com